Related Experiment Video

Updated: Aug 7, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Platinum-intercalator conjugates: from DNA-targeted cisplatin derivatives to adenine binding complexes as potential

Hemanta Baruah1, Colin G Barry, Ulrich Bierbach

  • 1Department of Chemistry, Wake Forest University, Winston-Salem, NC 27109-7486, USA.

Current Topics in Medicinal Chemistry
|December 8, 2004
PubMed

Insights

New platinum-intercalator conjugates offer novel DNA binding modes for cancer treatment. These agents, including adenine-specific minor-groove binders, represent a significant advancement in DNA-targeted chemotherapy drug discovery.

Area of Science:

  • Medicinal Chemistry
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Nuclear DNA is a primary target for cancer chemotherapies, with DNA-binding agents playing a crucial role in drug discovery.
  • Current DNA-targeted agents primarily interact through covalent binding, intercalation, or groove binding, influencing drug efficacy.
  • DNA-binding proteins and processing enzymes mediate cytotoxic effects, highlighting the importance of sequence- and groove-specific interactions.

Purpose of the Study:

  • To review advancements in the chemistry and biology of platinum-intercalator conjugates from 1984 to 2004.
  • To emphasize the relationship between chemical structure, DNA binding mechanisms, and biological activity.
  • To highlight the development of novel DNA adducts for new cell kill mechanisms in cancer treatment.

Main Methods:

  • Review of scientific literature focusing on platinum-intercalator conjugates.
  • Analysis of DNA adduct profiles resulting from various platinum-based agents.
  • Examination of sequence and regiospecificity of drug-DNA interactions.

Main Results:

  • Platinum-intercalator conjugates exhibit dual DNA binding modes, combining platinum's cross-linking with intercalator or groove-binding properties.
  • Traditionally, platinum agents form cross-links in guanine-rich regions within the major DNA groove.
  • Novel platinum-acridinylthiourea conjugates demonstrate adenine-specific minor-groove binding, breaking the established paradigm.

Conclusions:

  • The design of platinum-intercalator conjugates has expanded the repertoire of DNA-targeted anticancer agents.
  • The development of agents with novel DNA binding specificities, such as minor-groove directed binding, offers new therapeutic strategies.
  • Understanding the interplay between chemical structure and DNA interaction is key to developing more effective cancer chemotherapies.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC (Crosslinking of Small Molecules to Isolate Chromatin)10:05

Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC (Crosslinking of Small Molecules to Isolate Chromatin)

Published on: January 20, 2016

Related Concept Videos

Cis-regulatory Sequences02:02

Cis-regulatory Sequences

Cis-regulatory sequences are short fragments of non-coding DNA that are present on the same chromosomes as the genes that they regulate. These fragments serve as binding sites for transcriptional regulators, proteins that are responsible for controlling gene transcription and differential gene expression across cell types in eukaryotes. Cis-regulatory sequences can be close to the gene of interest or thousands of bases away in the DNA sequence; however, those sequences that are further away are...
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...